Cellectar Biosciences Inc. (NASDAQ:CLRB) is down 55% so far this year. The company has completed its Part A section of the tolerability and safety study of iopofosine I-131 in conjunction with external beam radiation in refractory or relapsed head and neck cancer.
The reduction infraction or amount of EBRT can possibly diminish the adverse events related to EBRT. Usually, head and neck cancer patients typically receive around 60-70 Grays for EVRT administered 2-3 GY daily doses in six weeks.
Interestingly patients can experience long-term tumor control after re-irradiation in the setting, and this approach can result in severer injury to normal tissue structures. The company’s Part B of the trial will evaluate the safety and possible benefits of iopofosine combination with EBRT in a cohort of 24 patients. CMO John Friend said they are optimistic that iopofosine combination with external beam ratio can offer enhanced outcomes for patients with the disease. So, in the coming months, CLRB is worth keeping an eye on.
Market Reaction:
On Wednesday, CLRB stock went up 2.26% at $0.9819 with more than 374K shares, compared to its average volume of 926k shares. The stock has moved within a range of $0.9680 – 0.9990 after opening the trade at $0.9831.
